Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ideaya Biosciences Inc (IDYA)

Ideaya Biosciences Inc (IDYA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,276,955
  • Shares Outstanding, K 87,666
  • Annual Sales, $ 7,000 K
  • Annual Income, $ -274,480 K
  • EBIT $ -216 M
  • EBITDA $ -235 M
  • 60-Month Beta 0.05
  • Price/Sales 15.34
  • Price/Cash Flow N/A
  • Price/Book 2.92

Options Overview Details

View History
  • Implied Volatility 119.51% (+0.48%)
  • Historical Volatility 38.48%
  • IV Percentile 96%
  • IV Rank 77.54%
  • IV High 140.84% on 04/07/25
  • IV Low 45.89% on 01/16/25
  • Expected Move (DTE 6) 5.30 (14.17%)
  • Put/Call Vol Ratio 10.71
  • Today's Volume 574
  • Volume Avg (30-Day) 1,125
  • Put/Call OI Ratio 0.31
  • Today's Open Interest 15,218
  • Open Int (30-Day) 10,109
  • Expected Range 32.08 to 42.68

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.03
  • Number of Estimates 5
  • High Estimate -0.82
  • Low Estimate -1.19
  • Prior Year -1.49
  • Growth Rate Est. (year over year) +30.87%

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.59 +14.70%
on 01/05/26
39.28 -4.84%
on 01/07/26
+3.30 (+9.68%)
since 12/09/25
3-Month
26.05 +43.49%
on 10/10/25
39.28 -4.84%
on 01/07/26
+10.59 (+39.53%)
since 10/09/25
52-Week
13.45 +177.92%
on 04/09/25
39.28 -4.84%
on 01/07/26
+12.53 (+50.42%)
since 01/08/25

Most Recent Stories

More News
Targeted Precision: Rare Disease Assets Attract Record Regulatory Momentum

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – Genomics-driven cancer diagnostics are accelerating market growth, with the genomics in cancer care market...

ONCY : 0.9677 (-2.41%)
IDYA : 37.38 (+2.61%)
ZLAB : 18.55 (+0.27%)
CHRS : 1.6900 (+10.46%)
HALO : 72.47 (+0.47%)
IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif. , Jan. 5, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...

IDYA : 37.38 (+2.61%)
IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma

SOUTH SAN FRANCISCO, Calif. , Dec. 11, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced it has completed its targeted full...

IDYA : 37.38 (+2.61%)
IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers

SOUTH SAN FRANCISCO, Calif. , Dec. 10, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, announced the submission of an investigational...

IDYA : 37.38 (+2.61%)
IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types

SOUTH SAN FRANCISCO, Calif. and SHANGHAI , Dec. 1, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development...

IDYA : 37.38 (+2.61%)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. , Nov. 28, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...

IDYA : 37.38 (+2.61%)
IDEAYA Biosciences to Participate in Upcoming December 2025 Investor Relations Events

SOUTH SAN FRANCISCO, Calif. , Nov. 24, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted...

IDYA : 37.38 (+2.61%)
Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director

IDYA : 37.38 (+2.61%)
TROW : 107.31 (-1.16%)
EXAS : 102.11 (+0.32%)
ILMN : 141.07 (-3.26%)
TMO : 618.86 (+2.04%)
SERA : 3.69 (+4.53%)
IR : 85.51 (+1.35%)
MTD : 1,485.12 (+1.36%)
QTRX : 8.06 (+23.81%)
LIFE : 1.9000 (+2.70%)
IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif. , Nov. 4, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, provided a business update and announced financial...

IDYA : 37.38 (+2.61%)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. , Oct. 31, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...

IDYA : 37.38 (+2.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

IDEAYA Biosciences Inc. is an oncology-focused precision medicine company. It focuses on the discovery and development of therapeutics for patients using molecular diagnostics. The company's product pipeline consists of IDE196, MAT2A, PARG, Pol-theta and WRN which are in clinical stage. IDEAYA Biosciences...

See More

Key Turning Points

3rd Resistance Point 39.46
2nd Resistance Point 38.75
1st Resistance Point 38.06
Last Price 37.38
1st Support Level 36.66
2nd Support Level 35.95
3rd Support Level 35.26

See More

52-Week High 39.28
Last Price 37.38
Fibonacci 61.8% 29.41
Fibonacci 50% 26.36
Fibonacci 38.2% 23.32
52-Week Low 13.45

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar